論文・技術情報追加のお知らせ

1. Newly identified adverse events for gemcitabine using the food and drug administration adverse event Reporting system.

ジェムシタビンの新たな副作用

対象DB：FAERS

2. Withdrawn 2.0-update on withdrawn drugs with pharmacovigilance data.

薬の副作用と再利用可能性

対象DB：FAERS

3. Characterizing Adverse Events of Biologic Treatment of T2 Disease: A Disproportionality Analysis of the FDA Adverse Event Reporting System.

T2疾患に関連したバイオロジクスの有害事象を比較

対象DB：FAERS

4. A pharmacovigilance study of association between proton-pump inhibitors and rhabdomyolysis event based on FAERS database.

PPIと横紋筋融解症の関連性

対象DB：FAERS

5. A disproportionality analysis of adverse events associated to pertuzumab in the FDA Adverse Event Reporting System (FAERS).

ペルツズマブの安全性のFAERS分析

対象DB：FAERS

6. A pharmacovigilance study of etoposide in the FDA adverse event reporting system (FAERS) database, what does the real world say?

抗腫瘍剤の実世界での有害事象

対象DB：FAERS

7. Thyroid dysfunction associated with iodine-contrast media: A real-world pharmacovigilance study based on the FDA adverse event reporting system.

ヨード造影剤(ICM)に関連する甲状腺機能障害

対象DB：FAERS

8. Facial palsy induced by immune checkpoint blockade: A systematic analysis of clinical trials and a pharmacovigilance study of postmarketing data.

免疫チェックポイント阻害薬(ICIs)と顔面神経麻痺のリスク

対象DB：FAERS

9. A Gender Hypothesis of sex disparities in adverse drug events.

ADE報告の性差：ジェンダー仮説の有望性

対象DB：FAERS

10. Psychiatric disorders associated with PCSK9 inhibitors: A real-world, pharmacovigilance study.

PCSK9iと精神の副作用：FAERSからのデータ解析

対象DB：FAERS

11. Adverse events of epidiolex: A real-world drug safety surveillance study based on the FDA adverse event reporting system (FAERS) database.

エピディオレックスの副作用調査: 新しい副作用発見

対象DB：FAERS

12. Enhancing Pharmacovigilance in Cote d'Ivoire: Impact of GSK's Training and Mentoring Pilot Project in the Abidjan Region.

コートジボワールのPVトレーニング：報告改善

対象DB：VigiBase

13. Pulmonary hypertension associated with diazoxide: the SUR1 paradox.

肺高血圧症(PH)の病態生理とジアゾキシドの矛盾した影響

対象DB：VigiBase

14. Big data- and machine learning-based analysis of a global pharmacovigilance database enables the discovery of sex-specific differences in the safety profile of dual IL4/IL13 blockade.

デュピルマブの性差に関する安全性調査

対象DB：VigiBase

15. Changes in surgery rates among hospitalized patients with inflammatory bowel disease in Japan from 2015 to 2019: A nationwide administrative database analysis.

日本における炎症性腸疾患治療の動向

対象DB：DPC

16. Relationship between carbapenem use and major diagnostic category in curative care beds: Analysis of a 2020 Japanese national administrative database.

カルバペネム使用の要因と対策

対象DB：DPC

17. Patient and Therapeutic Profiles of Pulmonary Hypertension in Chronic Lung Diseases in Japan: A Cohort Study Using a Claims Database.

慢性肺疾患の患者における肺高血圧に関する実態調査

対象DB：MDV

18. Healthcare resource utilisation and economic burden of patients with adequate and inadequate responses to biological and targeted synthetic disease-modifying antirheumatic drugs for rheumatoid arthritis in Japan.

RA治療の医療リソース利用と費用

対象DB：MDV

19. How is nicotine vaping product (e-cigarette) use monitored in primary care electronic health records in the United Kingdom? An exploratory analysis of Clinical Practice Research Datalink (CPRD).

英国の電子健康記録における電子たばこの記録

対象DB：CPRD

20. Continuity of care and consultation mode in general practice: a cross-sectional and longitudinal study using patient-level and practice-level data from before and during the COVID-19 pandemic in England.

COVID-19での診療モードとケアの連続性

対象DB：CPRD

21. The predictive accuracy of cardiovascular risk prediction tools in inflammatory arthritis and psoriasis: an observational validation study using the Clinical Practice Research Datalink.

炎症性疾患の心血管リスク予測ツールの精度

対象DB：CPRD

22. Ethnic inequities in routine childhood vaccinations in England 2006-2021: an observational cohort study using electronic health records.

母親の民族別に見る英国の子供のワクチン接種

対象DB：CPRD

23. Natural history of Duchenne muscular dystrophy in the United Kingdom: A descriptive study using the Clinical Practice Research Datalink.

CPRDを用いたDMD患者の生存率調査

対象DB：CPRD

24. Dipeptidyl peptidase-4 inhibitors and the risk of skin cancer among patients with type 2 diabetes: a UK population-based cohort study.

DPP-4阻害剤は悪性黒色腫の発生リスクを低減するが、非黒色腫皮膚癌との関連性は見られない

対象DB：CPRD

25. Assessing the cardiovascular effects of levothyroxine use in an ageing United Kingdom population (ACEL-UK) protocol: a cohort and target trial emulation study.

高齢者の甲状腺機能亢進の治療におけるレボチロキシンの影響を検討

対象DB：THIN